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ABSTRACT

Objective: To explore the association between metabolic syndrome and the Unified Parkinson’s
Disease Rating Scale (UPDRS) scores and, secondarily, the Symbol Digit Modalities Test (SDMT).

Methods: This is a secondary analysis of data from 1,022 of 1,741 participants of the National
Institute of Neurological Disorders and Stroke Exploratory Clinical Trials in Parkinson Disease
Long-Term Study 1, a randomized, placebo-controlled trial of creatine. Participants were categorized as having or not having metabolic syndrome on the basis of modified criteria from the
National Cholesterol Education Program Adult Treatment Panel III. Those who had the same metabolic syndrome status at consecutive annual visits were included. The change in UPDRS and
SDMT scores from randomization to 3 years was compared in participants with and without metabolic syndrome.

Results: Participants with metabolic syndrome (n 5 396) compared to those without (n 5 626)
were older (mean [SD] 63.9 [8.1] vs 59.9 [9.4] years; p , 0.0001), were more likely to be male
(75.3% vs 57.0%; p , 0.0001), and had a higher mean uric acid level (men 5.7 [1.3] vs 5.3 [1.1]
mg/dL, women 4.9 [1.3] vs 3.9 [0.9] mg/dL, p , 0.0001). Participants with metabolic syndrome
experienced an additional 0.6- (0.2) unit annual increase in total UPDRS (p 5 0.02) and 0.5- (0.2)
unit increase in motor UPDRS (p 5 0.01) scores compared with participants without metabolic
syndrome. There was no difference in the change in SDMT scores.

Conclusions: Persons with Parkinson disease meeting modified criteria for metabolic syndrome
experienced a greater increase in total UPDRS scores over time, mainly as a result of increases
in motor scores, compared to those who did not. Further studies are needed to confirm this
finding.
ClinicalTrials.gov identifier: NCT00449865. Neurology® 2017;89:1789–1794
GLOSSARY
ATP III 5 Adult Treatment Panel III; BMI 5 body mass index; NCEP 5 National Cholesterol Education Program; NET-PD LS 1 5
National Institute of Neurological Disorders and Stroke Exploratory Trials in PD Long-Term Study 1; PD 5 Parkinson disease;
SDMT 5 Symbol Digit Modalities Test; UPDRS 5 Unified Parkinson’s Disease Rating Scale.

Metabolic syndrome is a combination of conditions—hypertension, hyperglycemia, hyperlipidemia, and increased waist circumference—that, when occurring together, escalate a person’s
risk for heart disease, stroke, and diabetes mellitus. Recent studies suggest that the syndrome is
also associated with increased risk of other diseases,1–8 including Parkinson disease (PD).1,9
However, studies on the association of metabolic syndrome10 or its components,11–20 e.g.,
hyperglycemia or diabetes mellitus, and PD have yielded inconsistent results. For example, 2
recent meta-analyses of the association of diabetes mellitus and the risk of developing PD had
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opposite conclusions: one that diabetes mellitus increases the risk of PD21 and another that
it does not.22 Higher body mass index (BMI)
in midlife, i.e., .25 kg/m2, has been associated with an increased risk of PD in multiple
studies16,18,23 but not in others.19,24 A recent
study found that patients with PD with
increasing BMI had slower PD progression
than those with a stable or declining BMI25
as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS). Another study
reported that diabetes mellitus was associated
with more rigidity and a parkinsonian-type
gait in aging persons without a diagnosis of
PD or dementia.26
To the best of our knowledge, the effect of
metabolic syndrome on PD progression has
not previously been studied. The aim of this
study was to investigate the relationship
between metabolic syndrome and progression
of PD using change in UPDRS. Because metabolic syndrome may have a role in driving
cognitive impairment in PD, we also explored
the association of metabolic syndrome and
a cognitive measure. Using data from the
National Institute of Neurological Disorders
and Stroke Exploratory Trials in PD LongTerm Study 1 (NET-PD LS 1),27 we compared the progression of PD in those who
had metabolic syndrome throughout the first
3 years of the trial to those who were without
evidence of metabolic syndrome.
METHODS Participants. NET-PD LS 1 was a large, multicenter, placebo-controlled, randomized, double-blind trial of
10 mg creatine monohydrate vs placebo and was conducted from
March 2007 to September 2013. The study was terminated early,
when an interim analysis determined that creatine had no effect
on progression of PD.28 All participants had early-stage PD and
were on dopaminergic therapy at randomization. The study
design and characteristics of the population have been reported
previously.27
The NET-PD LS 1 study enrolled a total of 1,741 participants. Each participant was categorized as having metabolic syndrome or not at baseline and 1-, 2-, and 3-year visits. As a result of
missing data at any of these visits, we were unable to assess the
metabolic syndrome status of 319 participants. Furthermore,
only those who maintained the same metabolic syndrome status
for consecutive visits were included. Four hundred participants
experienced a change in their metabolic syndrome status during
the first 3 years of the study and were excluded from the analysis.
Therefore, of the 1,741 participants at baseline, 1,022 were
included in the final analysis.

Standard protocol approvals, registrations, and patient
consents. NET-PD LS 1 is registered on clinicaltrials.gov with
1790
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identifier NCT00449865. The institutional review boards of
each institution that participated approved the study, and all
participants signed informed consent.

Outcome measures. As part of NET-PD LS-1, UPDRS scores
for parts I, II, and III were assessed over time. Three outcome
measures were used for this study from baseline to the 3-year visit.
The primary outcome measure was the change in the total
UPDRS score (which we define here as parts I 1 II 1 III) from
the baseline (randomization) to the 3-year visit. The secondary
outcome measure was the change in the motor UPDRS (part III)
over the same time range. An additional outcome measure was the
Symbol Digit Modalities Test (SDMT) score,29 which was the
only cognitive test collected at annual visits.
Exposure. We categorized participants on the basis of the commonly agreed-on criteria from the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III),
which was updated in 2005.30 The NCEP criteria require 3 or
more of the following to be diagnosed with metabolic syndrome:
(1) waist circumference .35 in for women and .40 in for men,
(2) serum triglycerides $150 mg/dL (1.7 mmol/L) or medication
therapy for high triglycerides, (3) serum high-density lipoprotein
cholesterol ,50 mg/dL (1.3 mmol/L) in women and ,40 mg/dL
(1 mmol/L) in men or medication treatment for low high-density
lipoprotein cholesterol, (4) blood pressure $130/85 mm Hg or
on medication therapy for high blood pressure, and (5) fasting
plasma glucose $100 mg/dL (5.6 mmol/L) or on medication
therapy for high glucose.
Because the protocol for NET-PD LS 1 did not include waist
measurements or collection of cholesterol, triglyceride, or fasting
glucose levels, we adapted the ATP III criteria30 for use in our
study.30 Metabolic syndrome was defined as having 2 or more of
the following criteria: (1) BMI .30 kg/m2; (2) on statin medication; (3) systolic blood pressure .130 mm Hg, diastolic blood
pressure .85 mm Hg, or on antihypertensive medication; or (4)
random blood sugar .120 mg/dL or on antihyperglycemic medication. Criteria were the same for both sexes. Participants who no
longer fulfilled our modified criteria at subsequent visits were
excluded from the analysis to avoid misclassification bias. Using
these modified ATP III criteria, participants were classified into 2
groups: participants who had metabolic syndrome throughout the
3 years of the study and participants who were without evidence
of metabolic syndrome across all 3 years.
Statistical methods. Descriptive statistics (mean, SD, frequency, and percentages) were used to summarize the demographics for 2 groups: metabolic syndrome and no metabolic
syndrome. Differences in the mean or proportions between these
2 groups were checked by t test or x2 test.
The association of metabolic syndrome with the change in the
total and motor UPDRS and SDMT scores across time was estimated with a linear mixed model. Because the randomization
process included blocking by site, both site and treatment assignment (creatine vs placebo) were used as covariates.27
Metabolic syndrome, time in years, treatment group, and the
interaction term of metabolic syndrome and time in years were
tested in this model after adjustment for confounding variables:
baseline age, baseline total UPDRS, sex, handedness, race, uric
acid levels, and disease duration at baseline. Similarly, a second
model was adjusted for motor UPDRS score, and the only difference was the covariate baseline motor UPDRS instead of total
UPDRS score as stated before. A locally weighted scatterplot
smoothing plot for change in total UPDRS across time is presented to show the differences by group. The SDMT analysis,
using change in SDMT from baseline as the response variable,

Table 1

Baseline characteristics of participants (n 5 1,022) by metabolic
syndrome status

Demographics

No metabolic syndrome
(n 5 626), mean (SD)

Metabolic syndrome
(n 5 396), mean (SD)

p Value

Age, y

59.9 (9.4)

63.9 (8.1)

,0.0001

Male, n (%)

357 (57.0)

298 (75.3)

,0.0001

Disease duration, y

1.6 (1.1)

1.6 (1.1)

Total UPDRS score

25.0 (10.7)

26.0 (10.7)

0.16

Motor UPDRS score

17.0 (7.9)

17.7 (7.9)

0.14

Treatment with creatine, n (%)

310 (49.5)

188 (47.5)

0.52

Handedness: right, n (%)

560 (89.5)

352 (88.9)

0.78

Handedness: left/mixed, n (%)

66 (10.5)

44 (11.1)

0.78

White race, n (%)

586 (93.6)

365 (92.2)

0.38

Uric acid, men, mg/dL

5.3 (1.1)

5.7 (1.3)

,0.0001

Uric acid, women, mg/dL

3.9 (0.9)

4.9 (1.3)

,0.0001

0.92

Abbreviation: UPDRS 5 Unified Parkinson’s Disease Rating Scale.

predictors of baseline SDMT, metabolic syndrome status, time in
years, and the interaction term of metabolic syndrome and time
in years, was adjusted for confounding variables of baseline age,
total UPDRS score, sex, handedness, race, uric acid levels, and
disease duration.
All statistical analyses were conducted with SAS statistical
software (version 9.4, SAS Institute Inc, Cary, NC).

Sensitivity analyses. We considered alternative ways of analyzing the current dataset. We looked at the entire NET-PD LS1
cohort, dividing the metabolic vs no metabolic syndrome groups
according to their status at baseline, and followed them for their
entire participation in the study, up to 5 years, without regard to
whether they changed status at any annual visit. We also ran the
analyses with a stricter definition of metabolic syndrome, defining
metabolic syndrome as having 3 or more of the 4 criteria rather
than 2 or more as in the presented data. Furthermore, we ran the
analyses with different criteria for metabolic syndrome, considering that if participants were taking an antihypertensive, antihyperlipidemia, or antihypergylcemic medication, they would not
meet that criterion for metabolic syndrome because the indication
was adequately treated. Each of these sensitivity analyses produced the same results. Because the results were the same as those
presented here, they are not shown, but they are available on
request from the authors.

Table 1 shows the demographic characteristics of the participants for this study according to

RESULTS

Table 2

whether participants were categorized as having metabolic syndrome. Baseline mean age and mean uric
acid levels were significantly different in these 2
groups, as well as the proportion of men and women
in these 2 groups. Participants with metabolic syndrome were more likely to be men, to be older, and to
have a higher mean uric acid level compared to those
without metabolic syndrome.
Table 2 shows the change in total UPDRS over 3
years compared between the metabolic syndrome and
no metabolic syndrome groups. On average, participants without metabolic syndrome experienced a 1.7unit annual increase in total UPDRS score from their
baseline values, while participants with metabolic
syndrome experienced a 2.3- (1.7 1 0.6) unit annual
increase in total UPDRS change from baseline after
controlling for covariates. This information is also
presented in the figure, which demonstrates that participants with metabolic syndrome were more likely
to have increases in total UPDRS scores, especially in
the third year of study.
Table 3 shows the change in motor UPDRS (part
III) score, the secondary outcome measure, over 3
years compared between the 2 groups. On average,
participants without metabolic syndrome experienced
a 0.8-unit annual increase in their motor UPDRS
score, while participants with metabolic syndrome
experienced a 1.3- (0.8 1 0.5) unit increase per year.
Table 4 shows the change in SDMT. While the
SDMT declined 0.2 units (standard error 5 0.1) per
year (p 5 0.03), there was no significant difference,
0.3- vs 0.2-unit annual decline, between those with vs
without metabolic syndrome (p 5 0.77), respectively.
DISCUSSION This study shows that participants
with early-stage, treated PD who met modified criteria for metabolic syndrome had more rapid progression as measured by both the total and motor
UPDRS scores over time compared to those without
metabolic syndrome. This finding is consistent with
prior studies suggesting that the presence of metabolic
syndrome is associated with increased risk of developing PD, Alzheimer disease, cognitive decline, and
other diseases.1–8 We could find no other study

Change in total UPDRS

Effects
a

Metabolic syndrome

Estimate (SE)

95% CI

20.6 (0.5)

21.6 to 0.5

p Value
0.30

Time, y

1.7 (0.2)

1.4 to 2.0

,0.0001

Metabolic syndrome 3 time

0.6 (0.2)

0.1 to 1.0

0.02

Uric acid, mg/dL

0.2 (0.2)

20.1 to 0.5

0.29

Abbreviations: CI 5 confidence interval; SE 5 standard error; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
a
Metabolic syndrome is a dichotomized variable. In the model, the reference group is participants without metabolic
syndrome. The site and treatment assignment (creatine vs placebo) were included as covariates.
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Figure

Locally weighted scatterplot smoothing plot for change in total UPDRS

Sample size: 1,022 (assuming that the duration of 1 month is 30.5 days). UPDRS 5 Unified
Parkinson’s Disease Rating Scale.

showing an association between metabolic syndrome
and progression of PD, so this finding needs confirmation. If confirmed, this would raise the possibility
that improved treatment of metabolic syndrome
could offer a novel approach to slowing PD
progression.
How metabolic syndrome might accelerate PD
progression is not known. Because metabolic syndrome is a combination of conditions, each of these
conditions could contribute to the association. A
recent analysis of the NET-PD population found that
an increase in BMI was associated with a slower
increase in UPDRS scores, so it seems unlikely that
the high BMI component of metabolic syndrome
contributes strongly to the association of metabolic
syndrome and increasing UPDRS scores. Another
metabolic syndrome condition, hypertension, could
drive faster PD progression if it caused those affected
to have more CNS ischemia or strokes. Brain imaging
data were not collected in the NET-PD study, so this
theory cannot be substantiated with our data. Regarding blood trigyceride,23 glucose,23,31 and high-density

Table 3

Change in motor UPDRS
p Value

Effects

Estimate (SE)

95% CI

Metabolic syndrome

20.4 (0.4)

21.1 to 0.4

Time, y

0.8 (0.1)

0.6 to 1.0

Metabolic syndrome 3 time

0.5 (0.2)

0.2 to 0.8

0.01

Uric acid, mg/dL

0.2 (0.1)

20.1 to 0.4

0.14

0.34
,0.0001

Abbreviations: CI 5 confidence interval; SE 5 standard error; UPDRS 5 Unified Parkinson’s
Disease Rating Scale.
1792
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lipoprotein cholesterol levels, the literature to date is
conflicting, lacking, or not informative. Insulin resistance and inflammation underlie metabolic syndrome,32 and these pathologic mechanisms also
contribute to the progressive loss of dopaminergic
cells that results in PD.33,34 The association found
between metabolic syndrome and PD may therefore
be attributed to common pathophysiologic pathways.
The faster progression of motor signs in our participants with metabolic syndrome compared to those
without could be related to the accumulating evidence of brain abnormalities in the expression of insulin and insulin growth factors and their related
receptors and CNS insulin resistance being reported
in PD. Activities of insulin growth factors include
support of neuronal growth and survival. Recent literature suggests that these insulin-related CNS abnormalities may increase sensitivity to neurotoxins and
the accumulation of a-synuclein.35,36 While further
studies are needed to judge whether these brain
abnormalities correlate with clinical longitudinal
signs, given that patients with PD have CNS
insulin-related abnormalities that normally play a protective role, concurrent metabolic syndrome is likely
to exacerbate these baseline abnormalities and to
enhance the progression of disease.
While uric acid levels are not a defined component
of metabolic syndrome, the syndrome is associated
with higher uric acid levels. Studies to date suggest that
higher uric acid levels are associated with more slowly
increasing UPDRS scores.37,38 In this study, however,
the metabolic syndrome group had higher uric acid
levels and had faster increasing UPDRS scores.
The association of metabolic syndrome and cognitive function was explored in this study. In NET-PD,
the only cognitive measure captured at annual visits
was the SDMT score. There was no significant difference: 0.3- vs 0.2-unit annual decline in participants
with metabolic syndrome vs without (p 5 0.77).
However, this analysis was limited by the minimal
decline in SDMT scores that occurred in this early
treated PD group.39 Furthermore, the SDMT evaluates attention and not other cognitive domains or
global cognitive function.40
A strength of this study is that it is derived from
a relatively large and well-characterized cohort. In
addition, the results of the sensitivity analyses consistently generated the same result: those with metabolic
syndrome had greater increasing UPDRS scores over
time than those without metabolic syndrome. However the conclusions are limited by the use of a modified definition of metabolic syndrome. Therefore,
additional studies incorporating stricter measurements of the components of metabolic syndrome
are required to confirm the findings of this initial
study.

Table 4

2.

Change in SDMT

Effects
Metabolic syndrome

Estimate (SE)
0.2 (0.5)

95% CI
20.7 to 1.1

p Value
0.65

Time, y

20.2 (0.1)

20.4 to 0.1

0.03

Metabolic syndrome 3 time

20.1 (0.2)

20.5 to 0.3

0.77

0.1 (0.1)

20.2 to 0.3

0.70

Uric acid, mg/dL
SDMT baseline

20.2 (0.02)

20.2 to 20.1

3.

4.

,0.0001

Abbreviations: CI 5 confidence interval; SDMT 5 Symbol Digit Modalities Test; SE 5 standard error.

In NET-PD LS1, participants meeting criteria for
metabolic syndrome experienced a greater increase in
total UPDRS scores, mainly due to increases in motor
scores, compared to those not meeting these criteria.
If confirmed, future work should determine whether
treatment of metabolic syndrome results in a slower
increase in UPDRS scores over time.
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